Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease

OBJECTIVE: In patients with chronic coronary or peripheral artery disease enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, randomised antithrombotic treatments were stopped after a median follow-up of 23 months because of benefits of the combination of rivar...

Descripción completa

Detalles Bibliográficos
Autores principales: Dagenais, Gilles R, Dyal, Leanne, Bosch, Jacqueline J, Leong, Darryl P, Aboyans, Victor, Berkowitz, Scott D, Bhatt, Deepak L, Connolly, Stuart J, Fox, Keith A A, Muehlhofer, Eva, Probstfield, Jeffrey L, Widimsky, Petr, Winkelmann, Bernhard R, Yusuf, Salim, Eikelboom, John W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Cardiac Risk Factors and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257559/
https://www.ncbi.nlm.nih.gov/pubmed/34021038
http://dx.doi.org/10.1136/heartjnl-2020-318758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257559/
https://www.ncbi.nlm.nih.gov/pubmed/34021038
http://dx.doi.org/10.1136/heartjnl-2020-318758

Ejemplares similares